We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Adimab and DNA2.0 Enter Exclusive Antibody Discovery Relationship
News

Adimab and DNA2.0 Enter Exclusive Antibody Discovery Relationship

Adimab and DNA2.0 Enter Exclusive Antibody Discovery Relationship
News

Adimab and DNA2.0 Enter Exclusive Antibody Discovery Relationship

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Adimab and DNA2.0 Enter Exclusive Antibody Discovery Relationship"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Adimab, Inc., a pioneer in the integration of antibody discovery, maturation and biomanufacturing and DNA2.0, Inc. (Menlo Park, CA), the largest U.S. supplier of synthetic DNA today announce a strategic alliance in the area of antibody discovery.

The two companies have entered into an exclusive agreement to jointly develop and produce proprietary antibody libraries that replicate the human immune system’s ability to produce antibodies against any target.

“We did extensive diligence on the leading gene synthesis companies and DNA2.0 had an impeccable reputation amongst its customers. Their ability to work with us on the integration of all aspects of gene synthesis and library design was a major driver in this relationship,” says Dane Wittrup, Adimab co-founder and professor at MIT.

“Adimab brings a disruptive and novel approach to antibody discovery that has the potential to change the way we discover therapeutic antibodies in the future. We wanted to be part of that exciting development,” says Jeremy Minshull, DNA2.0 co-founder and president.

For more information, visit Adimab’s Partners

Advertisement